June 19, 2025

Get In Touch



Paroxetine Fails To Improve LVEF After Anterior MI: JAMA

Paroxetine when administered to patients does not improve LVEF after anterior myocardial infarction, suggests a study published in JAMA Cardiology.
Left ventricular remodeling following acute myocardial infarction often causes progressive myocardial dysfunction and adversely affects prognosis.
A study was conducted by Pilgrim T et. al to investigate the efficacy of paroxetine-mediated G-protein–coupled receptor kinase 2 inhibition to mitigate adverse left ventricular remodeling in patients presenting with acute myocardial infarction.
This study was double-blind, placebo-controlled a randomized clinical trial that was conducted at Bern University Hospital, Bern, Switzerland. Patients with acute anterior ST-segment elevation myocardial infarction with left ventricular ejection fraction (LVEF) of 45% or less was randomly allocated to 2 study arms between October 26, 2017, and September 21, 2020.
The authors selected a total of 50 patients with acute anterior myocardial infarction, of whom 38 patients underwent cardiac magnetic resonance imaging both at baseline and 12 weeks. These patients were randomly divided into either paroxetine orally for 12 weeks group or to the placebo group.
The primary endpoint was the difference in the patient-level improvement of LVEF between baseline and 12 weeks as assessed by cardiac magnetic resonance tomography. While secondary endpoints were changes in left ventricular dimensions and late gadolinium enhancement between baseline and follow-up.
The results of the study are as follows:
There was no difference in the recovery of LVEF between the experimental group and the control group or changes in left ventricular end-diastolic volume and end-systolic volume.
Late gadolinium enhancement as a percentage of the total left ventricular mass decreased to a larger extent in the experimental group compared with the control group.
The researchers concluded that in this trial, treatment with paroxetine did not improve LVEF after myocardial infarction compared with placebo.
Reference:
Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction by Pilgrim, T et. al published in the JAMA Cardiol.
doi:10.1001/jamacardio.2021.2247

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!